Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Research & Development (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Research & Development for 16 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 6.23% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, down 15.19% year-over-year, with the annual reading at $8.8 million for FY2025, 15.19% down from the prior year.
  • Research & Development for Q4 2025 was $2.2 million at Harvard Bioscience, up from $2.1 million in the prior quarter.
  • The five-year high for Research & Development was $3.5 million in Q2 2022, with the low at $2.1 million in Q3 2025.
  • Average Research & Development over 5 years is $2.7 million, with a median of $2.7 million recorded in 2021.
  • The sharpest move saw Research & Development soared 42.38% in 2021, then dropped 26.1% in 2024.
  • Over 5 years, Research & Development stood at $3.0 million in 2021, then fell by 3.46% to $2.8 million in 2022, then rose by 10.57% to $3.2 million in 2023, then decreased by 26.1% to $2.3 million in 2024, then dropped by 6.23% to $2.2 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.2 million, $2.1 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.